Analysis of the effect of mesalazine combined with bifidobacterium triple live bacteria in the treatment of ulcerative colitis
Objective To analyze the effect of mesalazine combined with bifidobacterium triple live bacteria in the treatment of ulcerative colitis(UC).Methods 97 UC patients were selected and divided into a control group(48 cases)and a study group(49 cases)according to random number table.The control group was treated with mesalazine,while the study group was combined with bifidobacterium triple live bacteria on the basis of the control group.Patients in both groups were compared in terms of clinical efficacy,ulcerative colitis disease activity index(UCDAI)score,serum inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]and the occurrence of adverse reactions.Results The total effective rate of the study group was 95.92%,which was higher than the control group's 81.25%(P<0.05).After 4 weeks of treatment,the study group had lower UCDAI score of(3.15±0.95)points than(5.40±0.90)points in the control group(P<0.05).After 4 weeks of treatment,the study group had TNF-α of(20.42±3.00)ng/L and IL-6 of(13.24±1.36)ng/L,which were lower than(29.65±3.47)and(19.35±1.50)ng/L in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of mesalazine combined with bifidobacterium triple live bacteria in the treatment of UC patients is reliable,which can effectively inhibit disease activity,improve inflammatory factor levels,and has clinical promotion value.
MesalazineBifidobacterium triple live bacteriaUlcerative colitis
NETL
NSTL
万方数据
